Teva Pharmaceutical Industries has appointed John Nason, Teva’s Senior Vice President of European Technical Operations, as President, Teva Active Pharmaceutical Ingredients (TAPI), a role in which he will lead the company’s vertically integrated business unit responsible for the development, manufacture, marketing, and sales of bulk APIs for both third-party manufacturers and Teva.

Nason also assumes responsibility for the company’s biologics operations. He will be based at Teva’s global headquarters in Petach Tikva, Israel and will report directly to Carlo de Notaristefani, Executive Vice President, Teva Global Operations.

Nason joined Teva in 2015 as Senior Vice President of European Technical Operations and worked with the company’s commercial and research and development organizations. In that position, Nason was a member of the operations leadership team responsible for setting strategy and managing Teva’s global operations, a role he will retain as President of TAPI and Teva’s biologics operations.

Prior to joining Teva, he served in a variety of senior leadership roles at Bristol-Myers Squibb where, over a period of 12 years, he led the company’s global API organization and third-party operations. Prior to that, he worked at Novartis, where he led bulk API manufacturing operations in Ireland and, earlier in his career, he held technical transfer, engineering and project management roles at Sandoz in the US on the design of a greenfield API site.

Source: Teva Pharmaceutical Industries